DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Bruix J, Tak WY, Gasbarrini A et al.
Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Eur J Cancer 2013;
49: 3412-3419
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.